Horizon Europe vs Eurostars: which non-dilutive funding fits a non-EU entrant.

Two programmes, two philosophies

It is tempting to treat EU non-dilutive funding as one bucket and chase whichever grant is largest. That instinct costs entrants time, because Horizon Europe and Eurostars are built on different philosophies. Horizon Europe exists to fund ambitious research and innovation that advances European priorities, frequently through collaborative consortia. Eurostars exists to help R&D-performing small and medium enterprises bring specific products closer to market, faster and with less overhead. One is a research engine; the other is an SME accelerant. Matching your company to the right philosophy matters more than the number on the grant.

When Horizon Europe fits

Horizon Europe fits a company with genuine research ambition and the capacity to manage scale. The grants are larger, the scope broader, and instruments like the EIC Accelerator can combine grant with investment for breakthrough innovation. But the process is longer and highly competitive, and many calls expect or reward multi-partner consortia spanning several countries. That consortium is an asset if you have the relationships to build it and the operational capacity to coordinate it — and a serious liability if you don't. Horizon Europe rewards companies that can credibly lead or join ambitious collaborative work, not those simply seeking the biggest cheque.

When Eurostars fits

Eurostars fits an R&D-performing SME with a defined product and a need to move. Projects are smaller and more focused, the process is generally faster, and the defining requirement is a collaboration with a partner in another participating country. For a company advancing a specific innovation toward market — common for medtech and deep-tech entrants — that cross-border partner requirement is very workable once the right relationship is in place, and the lighter overhead means the funding actually accelerates the product rather than consuming the team in administration.

The non-EU entrant's angle

For a company headquartered outside the EU, both programmes turn on establishment and relationships. Participation rules favour entities established in the EU or associated countries, which is one of the concrete reasons entering through Belgium matters: a Belgian entity can be positioned to participate, and the partner-country requirement that looks like a barrier becomes an advantage once you have credible consortium relationships in the Flemish and wider European ecosystem. This is where facilitation earns its place — not by guaranteeing a grant, but by structuring the entity and building the partner relationships so the route is genuinely open and the application arrives with context. Innovation Park provides that through direct working access to the ecosystem — namely VLAIO, FIT, imec, and EIT Health, among others — as facilitation, never a partnership with or guarantee from any funding body.

Choosing by stage

The decision rule is simple to state and easy to get wrong under the pull of a big number. If you have a defined product, a need for speed, and the ability to form one strong cross-border partnership, Eurostars is usually the better first move. If you have research ambition, the capacity to coordinate a larger consortium, and the patience for a longer process, Horizon Europe — potentially the EIC Accelerator — may be worth the effort. The biggest grant you cannot realistically win, or cannot absorb if you do, is worth less than the smaller one that actually lands and moves your product. Choose the route that fits where the company is, then build toward the larger ones from a funded position.

How to start.

Here is the fastest path to a real answer. No leap. A stair.